

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

## **DISCLOSEABLE TRANSACTION COMPLETION OF THE PROPOSED ACQUISITION OF TASLY PHARMACEUTICALS**

This announcement is made by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcements dated 4 August 2024 (the “**Announcement**”) made by the Company in relation to the Proposed Acquisition of 28% interest in Tasly Pharmaceuticals Group Co., Ltd. (天士力醫藥集團股份有限公司) (“**Tasly Pharmaceuticals**”) by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (華潤三九醫藥股份有限公司) (“**CR Sanjiu**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

### **COMPLETION OF THE PROPOSED ACQUISITION**

The Board is pleased to announce that CR Sanjiu has received a confirmation issued by China Securities Depository and Clearing Corporation Limited on 27 March 2025, confirming that the transfer of 418,306,002 shares in Tasly Pharmaceuticals (representing 28% interest in Tasly Pharmaceuticals as at the date of this announcement) has been completed. Accordingly, as of the date of this announcement, the Proposed Acquisition by CR Sanjiu of 28% interest in Tasly Pharmaceuticals pursuant to the terms of the Share Purchase Agreement has been completed, and Tasly Pharmaceuticals has become a non-wholly-owned subsidiary of the Company. CR Sanjiu will settle the remainder of the consideration for the Proposed Acquisition in accordance with the terms of the Share Purchase Agreement.

*For ease of reference, the names of the PRC established companies or entities have been included in this announcement in both the Chinese and English languages, and in the event of any inconsistency, the Chinese version shall prevail.*

By order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Mr. Bai Xiaosong**  
*Chairman*

PRC, 27 March 2025

*As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*